Preliminary validation of the NTM module: a patient-reported outcome measure for patients with pulmonary nontuberculous mycobacterial disease.
Nontuberculous mycobacteria (NTM) cause chronic, debilitating pulmonary disease. Patient-reported outcomes (PRO) provide measures of symptoms, functioning, and treatment response. Here we describe the preliminary validation of the recently developed NTM Module. The study population included Northwest NTM Biobank patients who isolated Mycobacterium avium complex (MAC) and ever met 2007 ATS/IDSA pulmonary disease criteria. The NTM Module was administered at enrolment and 12 months; a subset also completed the QOL-Bronchiectasis (QOL-B). The NTM Module generates four domain scores (0-100; higher scores=better functioning) reflecting NTM-specific symptoms (NTM Symptoms, Body Image, Digestive Symptoms, and Eating Problems). We described patient characteristics, mean scores, and evaluated psychometric properties, including responsivity to treatment at 12 months, for each domain. Overall, 203 patients with pulmonary MAC disease were included. Average enrolment scores ranged from 76 (NTM Symptoms) to 84 (Eating Problems). Ceiling effects were observed for Body Image (26%) and Eating Problems (52%). Internal consistency (Cronbach's alpha) ranged from 0.67 (Digestive Symptoms) to 0.89 (Eating Problems). The intra-class correlation for test-retest reproducibility (N=27) ranged from 0.72 (Body Image) to 0.94 (Eating Problems). Patients starting treatment (N=35) had statistically significant increases in scores for NTM Symptoms (+5, p=0.04), Digestive Symptoms (+7, p=0.002), Body Image (+7, p=0.03) and QOL-B Respiratory Symptoms (N=25, +10, p=0.006). NTM Symptoms scores increased 15 points (p=0.002) in the 16 patients with scores ≤80 at enrolment. The NTM Module generally performs well as a valid PRO for pulmonary MAC disease and was responsive to MAC treatment.